Global Electronic Drug Delivery Systems Market to Reach $21.5 Billion by 2030
The global market for Electronic Drug Delivery Systems estimated at US$10.6 Billion in the year 2022, is projected to reach a revised size of US$21.5 Billion by 2030, growing at a CAGR of 9.2% over the analysis period 2022-2030. Wearable Infusion Pumps, one of the segments analyzed in the report, is projected to record 8.9% CAGR and reach US$8.7 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Auto Injectors segment is readjusted to a revised 9.4% CAGR for the next 8-year period.The U.S. Market is Estimated at $2.9 Billion, While China is Forecast to Grow at 14.7% CAGR
The Electronic Drug Delivery Systems market in the U.S. is estimated at US$2.9 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$5.3 Billion by the year 2030 trailing a CAGR of 14.7% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4% and 7.8% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 5.2% CAGR.Select Competitors (Total 42 Featured) -
- Amgen, Inc.
- Astrazeneca PLC
- Bayer AG
- Canè SPA
- Companion Medical
- Debiotech S.A.
- F.Hoffmann-La Roche, Ltd.
- Findair SP. Z O. O.
- Insulet Corporation
- Medtronic PLC
- Merck Group
- Novo Nordisk
- Tandem Diabetes Care, Inc.
- United Therapeutics Corporation
- Vicentra B.V.
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIII. MARKET ANALYSISCANADAITALYSPAINRUSSIAREST OF EUROPESOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
UNITED KINGDOM
ASIA-PACIFIC
AUSTRALIA
INDIA
LATIN AMERICA
MIDDLE EAST
AFRICA
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Amgen, Inc.
- Astrazeneca PLC
- Bayer AG
- Canè SPA
- Companion Medical
- Debiotech S.A.
- F.Hoffmann-La Roche, Ltd.
- Findair SP. Z O. O.
- Insulet Corporation
- Medtronic PLC
- Merck Group
- Novo Nordisk
- Tandem Diabetes Care, Inc.
- United Therapeutics Corporation
- Vicentra B.V.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 93 |
Published | May 2024 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 10.6 Billion |
Forecasted Market Value ( USD | $ 21.5 Billion |
Compound Annual Growth Rate | 9.2% |
Regions Covered | Global |